Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
4.810
-0.160 (-3.22%)
At close: Oct 8, 2025, 4:00 PM EDT
4.900
+0.090 (1.87%)
After-hours: Oct 8, 2025, 7:44 PM EDT
LIXT Employees
Lixte Biotechnology Holdings had 2 employees as of December 31, 2024. The number of employees decreased by 2 or -50.00% compared to the previous year.
Employees
2
Change (1Y)
-2
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,544,476
Market Cap
21.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | -2 | -50.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | 0 | - |
| Dec 31, 2020 | 4 | 3 | 300.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LIXT News
- 22 days ago - LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT) - Accesswire
- 23 days ago - LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT) - Accesswire
- 4 weeks ago - LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions - GlobeNewsWire
- 4 weeks ago - 24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor - Newsfile Corp
- 5 weeks ago - LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer - GlobeNewsWire
- 6 weeks ago - 24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy - GlobeNewsWire
- 6 weeks ago - 24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets - GlobeNewsWire
- 7 weeks ago - 24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100 - GlobeNewsWire